EBS
Emergent BioSolutions Inc.
EBS's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over EBS overall, supported by stronger fundamentals and lower modeled downside.
EBS Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Strong | |
| Weak |
EBS's cash flow is currently strong, and its revenue is stable, but its profitability and balance sheet are weak.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
EBS PE Valuation
EBS has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 16x next year's earnings.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
EBS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect EBS to return to profit, with revenue growing.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
EBS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.38 | — |
| Q3 2026 | -$5.01 | -450% |
| Q2 2026 | -$3.46 | -234% |
| Q1 2026 | -$0.19 | +$2.39 |
| Q4 2025 | $0.93 | +$4.53 |
| Q3 2025 | $1.43 | +$5.48 |
| Q2 2025 | $2.58 | +$13.77 |
| Q1 2025 | -$2.58 | +$8.38 |
| Q4 2024 | -$3.60 | +$11.18 |
EBS has swung to a loss: it lost $5.01 per share over the past year, after a profit the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over EBS on earnings quality, reporting a profit while its opponent remains loss making.
EBS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $110M | -52% |
| Q2 2026 | $234.3M | +66% |
| Q1 2026 | $156.1M | -30% |
| Q4 2025 | $148.7M | -24% |
| Q3 2025 | $231.1M | -21% |
| Q2 2025 | $140.9M | -45% |
| Q1 2025 | $222.2M | -26% |
| Q4 2024 | $194.7M | -30% |
EBS's revenue has slid since its 2021 peak: $110M last quarter, down 52% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -34% | -67 points |
| Q2 2026 | -53% | -55 points |
| Q1 2026 | 6.7% | -16 points |
| Q4 2025 | -19% | -14 points |
| Q3 2025 | 33% | +11 points |
| Q2 2025 | 1.1% | +81 points |
| Q1 2025 | 22% | +9.2 points |
| Q4 2024 | -4.9% | +11 points |
EBS's operating margin was −34% last quarter, down 67 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over EBS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over EBS on profitability, with a higher operating margin.
EBS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $96.8M | +$102.5M |
| Q2 2026 | $54M | -48% |
| Q1 2026 | -$36.2M | -$21.4M |
| Q4 2025 | $73.8M | +$155.4M |
| Q3 2025 | -$5.7M | -104% |
| Q2 2025 | $103.5M | +141% |
| Q1 2025 | -$14.8M | +$58.6M |
| Q4 2024 | -$81.6M | -494% |
EBS still generates free cash flow, though less than at its 2021 peak: $188M over the past year.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over EBS on cash flow, with more consistent year-over-year improvement.
EBS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.6% | -300K shares |
| 1 year | -9.2% | -5.2M shares |
| 3 years | -1% | -500K shares |
| 5 years | -4.5% | -2.4M shares |
| Available history | -2.1% | -1.1M shares |
EBS has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $100,000 |
| Q2 2026 | $9M |
| Q1 2026 | $9M |
| Q4 2025 | $9.1M |
| Q3 2025 | $8.9M |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
EBS spent $27M buying back its own shares over the past year.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
EBS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 15.6x | High |
| Q1 2026 | 2.7x | Moderate |
| Q4 2025 | 1.9x | Healthy |
| Q3 2025 | 1.9x | Healthy |
| Q2 2025 | 1.9x | Healthy |
| Q1 2025 | 67.1x | High |
| Q4 2024 | 5,642.0x | High |
| Q3 2021 | 1.1x | Healthy |
EBS's net debt is about 16 years of its operating earnings (EBITDA), up from 1.9 years a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over EBS on leverage, with a lower net debt burden relative to earnings.
EBS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.0 | Neutral |
| Stochastic | 56.9 | Neutral |
EBS's weekly RSI is 42 (neutral) and its Stochastic is 57 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
EBS PE vs Healthcare Sector
| Metric | EBS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
EBS has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
EBS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.44 | 8.5% below |
| 20 week MA | $6.48 | 9.1% below |
| 50 week MA | $8.41 | 30% below |
| 100 week MA | $8.14 | 28% below |
| 200 week MA | $7.37 | 20% below |
EBS is in a downtrend: it's below all five of its weekly moving averages, and 20% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over EBS on trend strength, trading above more of its moving averages.
EBS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $54.0 | $93.8 | +74% |
| 2021 | $93.8 | $45.5 | -51% |
| 2022 | $45.5 | $11.0 | -76% |
| 2023 | $11.0 | $2.40 | -78% |
| 2024 | $2.40 | $8.27 | +245% |
| 2025 | $8.27 | $12.4 | +50% |
| 2026 YTD | $12.4 | $5.89 | -53% |
EBS's yearly returns have swung widely, from +245% in 2024 to −78% in 2023. It's down 53% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over EBS on returns for 2026, with the stronger performance.